<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04951570</url>
  </required_header>
  <id_info>
    <org_study_id>CATCH-AI</org_study_id>
    <nct_id>NCT04951570</nct_id>
  </id_info>
  <brief_title>Clinical Diagnosis and Treatment of Intracerebral Hemorrhage Based on Artificial Intelligence</brief_title>
  <acronym>CATCH-AI</acronym>
  <official_title>Clinical Diagnosis and Treatment of Intracerebral Hemorrhage Based on Artificial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the reliability and validity of an artificial&#xD;
      intelligence system and a related 5-score scale to predict hematoma expansion, and conduct a&#xD;
      study cohort of intracerebral hemorrhage to screen out imaging and biological markers that&#xD;
      could predict hematoma expansion in real-world.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a investigator-initiated, multi-center, prospective, registered cohort study. The&#xD;
      study is intended to enroll 4000 patients with intracerebral hemorrhage from 50 hospital in&#xD;
      China. Clinical and imaging data, as well as the results of laboratory examination will be&#xD;
      collected to test the reliability and validity of an artificial intelligence system and a&#xD;
      related 5-score scale to predict hematoma expansion, and conduct a study cohort of&#xD;
      intracerebral hemorrhage to screen out imaging and biological markers that could predict&#xD;
      hematoma expansion in real-world.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 8, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 8, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>hematoma expansion</measure>
    <time_frame>24-48 hours from symptom onset</time_frame>
    <description>non-contrast CT scan: the enlargement of hematoma ≥6ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence of intracerebral hemorrhage</measure>
    <time_frame>90 days from symptom onset</time_frame>
    <description>non-contrast CT scan: non-traumatic intracerebral hemorrhage other than the primary hemotoma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional dependence</measure>
    <time_frame>3 months</time_frame>
    <description>modified Rankin Scale score ≥3 (a global measure of disability on a seven-level scale, with scores ranging from 0 (no symptoms) to 6 (death), higher scores mean a better or worse outcome )</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebrovascular death</measure>
    <time_frame>3 months</time_frame>
    <description>Death due to one of the following events: ischemic stroke or hemorrhagic stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>3 months</time_frame>
    <description>Death due to one of the following events: sudden cardiac death or acute myocardial infarction or heart failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New ischemic stroke</measure>
    <time_frame>3 months</time_frame>
    <description>Acute focal neurological impairment corresponding with infarction on CT/MR scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New subarachnoid hemorrhage</measure>
    <time_frame>3 months</time_frame>
    <description>Hemorrhage in subarachnoid space proven on CT/MR scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other cardiovascular events</measure>
    <time_frame>3 months</time_frame>
    <description>One of the following events: non-fatal myocardial infarction or non-fatal heart failure</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Hematoma Expansion (HE) group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>non-HE group</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples and urine samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with sICH that arrived at hospital within 24 hours.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of spontaneous intracerebral hemorrhage(sICH)&#xD;
&#xD;
          2. Age ≥18;&#xD;
&#xD;
          3. Admission within 24 hours of symptom onset&#xD;
&#xD;
          4. CT available at 24 hours&#xD;
&#xD;
          5. Informed consent obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Intracerebral hemorrhage caused by tumor, vascular malformation, aneurysm, etc.&#xD;
&#xD;
          2. Deep coma at admission (GCS≤8)&#xD;
&#xD;
          3. Intended to have a surgery within 24 hours&#xD;
&#xD;
          4. Congenital coagulation dysfunction&#xD;
&#xD;
          5. Previous intracerebral hematoma have not been absorbed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Xingquan Zhao</investigator_full_name>
    <investigator_title>Professor of Neurology and Stroke Center</investigator_title>
  </responsible_party>
  <keyword>Intracerebral Hemorrhage</keyword>
  <keyword>Hematoma Expansion</keyword>
  <keyword>Artificial Intelligence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

